VEGFA and retinal vascular occlusion: This is consistent with a recent meta-analysis using a random-effects model including 14 randomized controlled trials on 6759 eyes, with no difference in the risk of severe sight-threatening IOI outcomes and retinal vascular occlusion between different anti-VEGF agents.